Lantheus (NASDAQ:LNTH) Stock Price Crosses Above Fifty Day Moving Average - What's Next?

Key Points

• Lantheus shares crossed above their 50-day moving average, trading around $100.39 versus the average of $100.35, up 0.5% during the session.
• Analyst sentiment is cautious: three analysts rate Lantheus a Buy and eleven rate it Hold, producing a consensus Hold rating and an average price target of $107.44.
• The company exceeded quarterly expectations with $1.55 in EPS and $388.18 million in revenue, while institutional investors own approximately 99.06% of the outstanding shares.

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report)'s stock price crossed above its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $100.35 and traded as high as $100.40. Lantheus shares last traded at $100.39, with a volume of 1,330,006 shares traded.

Analyst Upgrades and Downgrades

LNTH has been the subject of several recent research reports. Weiss Ratings cut shares of Lantheus from a "hold (c+)" rating to a "hold (c)" rating in a research report on Thursday, October 15th. CJS Securities downgraded shares of Lantheus from a "market outperform" rating to a "market perform" rating in a research note on Tuesday, August 4th. TD Cowen lowered shares of Lantheus from a "buy" rating to a "hold" rating and cut their price target for the stock from $110.00 to $102.50 in a report on Monday, August 3rd. Leerink Partners set a $102.50 price objective on shares of Lantheus in a research note on Monday, August 3rd. Finally, B. Riley Financial cut shares of Lantheus from a "buy" rating to a "hold" rating in a research note on Monday, August 17th. Three analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $107.44.

Lantheus Stock Up 0.5%

The company has a quick ratio of 2.89, a current ratio of 3.06 and a debt-to-equity ratio of 0.43. The stock's 50-day simple moving average is $100.35 and its 200 day simple moving average is $98.24. The firm has a market cap of $6.56 billion, a P/E ratio of 24.25 and a beta of -0.06.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.30 by $0.25. The firm had revenue of $388.18 million during the quarter, compared to analyst estimates of $363.23 million. Lantheus had a return on equity of 28.10% and a net margin of 17.69%. The business's quarterly revenue was up 2.7% on a year-over-year basis. During the same period last year, the company posted $1.57 EPS. As a group, research analysts forecast that Lantheus Holdings, Inc. will post 4.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Lantheus

A number of institutional investors and hedge funds have recently modified their holdings of LNTH. ABS Investment Management LLC purchased a new position in shares of Lantheus in the 2nd quarter worth about $232,974,000. Western Wealth Management LLC bought a new position in Lantheus during the first quarter valued at about $25,000. USA Financial Formulas bought a new position in Lantheus during the third quarter valued at about $41,000. Allworth Financial LP bought a new position in Lantheus during the second quarter valued at about $49,000. Finally, Bessemer Group Inc. increased its holdings in Lantheus by 221.2% during the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider's stock worth $39,000 after buying an additional 354 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc is a diagnostic imaging and radiopharmaceutical company that develops, manufactures and commercializes products used to help physicians detect, characterize and monitor disease. Its portfolio supports imaging in areas including oncology, cardiology and other medical specialties.

The company's products include DEFINITY, an ultrasound-enhancing agent used in cardiac and other ultrasound examinations, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and manage prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.